EUVIMEDEUVIMED entdecken
Crossref

Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer

Tadayoshi Hashimoto iD, Satoshi Otsu, Shuichi Hironaka, Atsuo Takashima, Junki Mizusawa, Tomoko Kataoka, Haruhiko Fukuda, Shunsuke Tsukamoto, Tetsuya Hamaguchi, Yukihide Kanemitsu

Future Oncology · 2023

DOI: 10.2217/fon-2023-0097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Oncology, 2023. Verfasst von Tadayoshi Hashimoto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapy plus antiangiogenic agents, including bevacizumab, ramucirumab and aflibercept, is a standard second-line treatment for patients with metastatic colorectal cancer, but which specific agents should be selected is ambiguous due to a lack of clear evidence from prospective studies. Previous reports have suggested ramucirumab and aflibercept could be more effective than bevacizumab in patients with high VEGF-D and high VEGF-A, respectively. JCOG2004 is a three-arm, randomized, phase II study to identify predictive biomarkers for these agents in patients who have failed first-line treatment. The study will enroll 345 patients from 52 institutions for 2 years, with progression-free survival in high VEGF-D (bevacizumab vs ramucirumab) and high VEGF-A (bevacizumab vs aflibercept) serving as the primary end point. Clinical Trial Registration: jRCTs031220058 (www.jrct.niph.go.jp).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsColonic NeoplasmsRectal NeoplasmsHumansBevacizumabVascular Endothelial Growth Factor DVascular Endothelial Growth Factor AOxaliplatinCamptothecinProspective StudiesFluorouracilBiomarkersLeucovorinAntineoplastic Combined Chemotherapy ProtocolsClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

afliberceptbevacizumabmetastatic colorectal cancerphase II studypredictive biomarkerramucirumab

Substanzen

BevacizumabVascular Endothelial Growth Factor DVascular Endothelial Growth Factor AOxaliplatinCamptothecinFluorouracilBiomarkersLeucovorin

Autor:innen und Institutionen

  • Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Medical Oncology & Hematology, Oita University Faculty of Medicine, Yufu, Japan.
  • Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.
  • Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Gastroenterological Oncology, Saitama Medical University International Medical Center, Saitama, Japan.

ORCID-Profile: Tadayoshi Hashimoto

Zitieren

APA

Hashimoto, T., Otsu, S., Hironaka, S., Takashima, A., Mizusawa, J., Kataoka, T., Fukuda, H., Tsukamoto, S., Hamaguchi, T., & Kanemitsu, Y. (2023). Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer. Future Oncology. https://doi.org/10.2217/fon-2023-0097

Vancouver

Hashimoto T, Otsu S, Hironaka S, Takashima A, Mizusawa J, Kataoka T, et al. Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer. Future Oncology. 2023. doi:10.2217/fon-2023-0097

BibTeX
@article{Hashimoto2023,
  author = {Hashimoto, Tadayoshi and Otsu, Satoshi and Hironaka, Shuichi and Takashima, Atsuo and Mizusawa, Junki and Kataoka, Tomoko and Fukuda, Haruhiko and Tsukamoto, Shunsuke and Hamaguchi, Tetsuya and Kanemitsu, Yukihide},
  title = {Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer},
  journal = {Future Oncology},
  year = {2023},
  doi = {10.2217/fon-2023-0097}
}
Kostenlos starten →